Treatment of Parkinson's Disease With a Transdermal Skin Patch
Status:
Completed
Trial end date:
2001-01-01
Target enrollment:
Participant gender:
Summary
Patients with Parkinson's disease are missing the chemical neurotransmitter dopamine. This
occurs as a result of destructive changes in an area of the brain responsible for making
dopamine, the basal ganglia. Muscle tremors, rigidity of movement, shuffling footsteps,
droopy posture, and a mask-like expression on the face characterize Parkinson's disease.
This study is designed to determine the effects of a new drug, N-9023. The drug acts like
dopamine and can be given through a skin patch (transdermal) for treatment of parkinsonian
symptoms.
The goals of this study are to find out whether N-9023 is useful in treating the signs and
symptoms of Parkinson's disease and to determine the best dose of N-9023 that is safe and
effective.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Neurological Disorders and Stroke (NINDS)